Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase 1 Trial

PURPOSE: This dose-finding phase 1 study investigated the maximum tolerated dose (MTD) and safety of weekly nab-rapamycin in patients with untreatable advanced nonhematologic malignancies. EXPERIMENTAL DESIGN: nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a start...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Gonzalez-Angulo, Ana M., Meric-Bernstam, Funda, Chawla, Sant, Falchook, Gerald, Hong, David, Akcakanat, Argun, Chen, Huiqin, Naing, Aung, Fu, Siqing, Wheler, Jennifer, Moulder, Stacy, Helgason, Thorunn, Li, Shaoyi, Elias, Ileana, Desai, Neil, Kurzrock, Razelle
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3935482/
https://ncbi.nlm.nih.gov/pubmed/24089446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3110
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы